Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Exactech (EXAC) -- Ignore unavailable to you. Want to Upgrade?

To: Steven Dopp who wrote (93)	3/4/1999 9:33:00 AM
From: Robert G. Harrell	Read Replies (1) \| Respond to of 118

Just received this from the company's PR firm. I taped the CC and took notes but just haven't had time to write them up in a post. I'll try to do that this week. Bob Today, LaSalle St. Securities Inc. analyst William J. Plovanic issued a report highlighting Exactech's (EXAC - Nasdaq) fourth quarter 1998 and full year 1998 results. In addition, revenue and EPS estimates were raised for fiscal 1999 and projections were instituted for fiscal 2000. Furthermore, the Intermediate Term BUY rating and Long Term STRONG BUY ratings were reiterated with a $20.00 12-18 month price target. Mr. Plovanic stated that EXAC's sales increased in excess of 36% for fiscal 1998 while EPS grew 35%. More importantly, sales of Opteform (EXAC's biological bone product), increased over 3* fold to $414,000 for the quarter and finished the year with total sales of $608,000. Mr. Plovanic raised projections for Opteform sales to $3.0 million from $1.4 million for 1999 and instituted Opteform sales projections of $6.0 million for fiscal 2000. LaSalle St. Securities' earnings estimates are as follows: Qtr Revenues EPS 1Q99 $7.0 mln $0.13 2Q99 $7.1 mln $0.13 3Q99 $7.2 mln $0.13 4Q99 $9.1 mln $0.18 1999 $30.4 mln $0.58# 2000 $38.6 mln $0.78 #may not add up due to rounding